| Recruitment status | Enrolling by invitation |
| Unique ID issued by UMIN | UMIN000021724 |
| Receipt No. | R000025057 |
| Official scientific title of the study | Influences of the huge earthquake-associated disaster on the clinical symptoms and radiographic findings in patients with non-tuberculous mycobacterium (NTM) |
| Date of disclosure of the study information | 2016/03/31 |
| Last modified on | 2016/03/31 (Ver. 1) |
| Basic information | ||
| Official scientific title of the study | Influences of the huge earthquake-associated disaster on the clinical symptoms and radiographic findings in patients with non-tuberculous mycobacterium (NTM) | |
| Title of the study (Brief title) | Influences of the huge earthquake-associated disaster on the clinical symptoms and radiographic findings in patients with non-tuberculous mycobacterium (NTM) | |
| Region |
|
|
| Condition | ||
| Condition | non-tuberculous mycobacterium (NTM) | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To examine the influences of the disaster on the non-tuberculous mycobacterium (NTM) disease state in the patients who are living in the around areas of disasters.
|
| Basic objectives2 | Others |
| Basic objectives -Others | |
| Trial characteristics_1 | Others |
| Trial characteristics_2 | Others |
| Developmental phase | |
| Assessment | |
| Primary outcomes | clinical symptoms and radiographic findings before and after the disaster |
| Key secondary outcomes | association between stress disoder scores and NTM features after disasters |
| In outcomes field, the entry of just a few words such as "safety" or "efficiency" will not be accepted. Specify the name of outcome measures, including the time when you plan to measure. Usually, only one primary outcome is accepted. Write the other outcomes in "secondary outcomes" field. |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| In interventions field, include the details of interventions, such as duration, amount, and frequency. If the intervention includes prescription or use of medical devices, duration is required. |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Patientsdiagnozed as NTM whom M. avium or M.intercellurare was identified from sputum culture
Patients lived in Japan at 11th March, 2011. |
|||
| Key exclusion criteria | (1) Coexistence of other major pulmonary diseases such as asthma, bronchiectasis, pulmonary fibrosis, tuberculosis, and pulmonary cancer diagnosed by imaging modalities and/or laboratory findings. Asthma is excluded based on clinical history and/or laboratory findings, including levels of IgE and/or eosinophils in blood and/or sputum, but not based on reversibility of airflow limitation.
(2)patients with cancers (3)patients with other serious complocations (4) Those who are considered as inappropriate subjects for any reasons. |
|||
| Target sample size | 100 | |||
| Research contact person | |
| Name of lead principal investigator | Shinji Teramoto |
| Organization | Hitachinaka General Hospital |
| Division name | Department of pulmonary medicine |
| Address | 20-1 Ishikawa-cho, Hitachinaka-shi, Ibaraki,Japan 312-0057 |
| TEL | 029-354-5111 |
| shinjit-tky@umin.ac.jp | |
| Public contact | |
| Name of contact person | Shinji Teramoto |
| Organization | Hitachinaka General Hospital |
| Division name | Department of pulmonary medicine |
| Address | 20-1 Ishikawa-cho Hitachinaka-shi |
| TEL | 029-354-5111 |
| Homepage URL | |
| shinjit-tky@umin.ac.jp | |
| Sponsor | |
| Institute | Hitachinaka General Hospital |
| Institute | |
| Department | |
| Sponsor means an organization that is responsible for plan, deployment and report of the research including funding management. It doesn't mean funding agency". Therefore, all clinical trial should have the one. |
| Funding Source | |
| Organization | Hitachinaka General Hospital |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Enrolling by invitation | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | The results will be presented in the Journals. |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-bin/ctr_e/ctr_view.cgi?recptno=R000025057 |